Cantor Fitzgerald, Goldman Sachs and Zacks also have a “buy” rating on the stock, according to the report.
AmSurg has a 52-week low of $44.61 and 52-week high of $70.53.
More articles on transactions and valuation issues:
Surgery Center South in Alabama files CON for expansion
New ASC opening at Rockaway Beach: 8 things to know
SurgCenter Development, physicians to open $2M JV surgery center in Ohio: 3 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.